GLP-1 weight loss drugs like Ozempic may be associated with an increased risk of smell and taste disturbances.

Read Full Article

#GLP1 #WeightLoss #TasteAndSmellDisorders

Researchers show that intermittent fasting maintains long-term weight loss, regardless of meal timing. Findings offer valuable flexibility for patients to choose the schedule that best suits their lifestyle, thereby improving adherence and success in obesity treatment.

Read Full Article

#IntermittentFasting #WeightLoss #ObesityTreatment

📈 A study involving 99 overweight or obese adults, including half women, demonstrated that a 12-week intermittent fasting regimen (16 hours fasting, 8 hours eating) helps maintain weight loss for 12 months post-intervention.

🏋️‍♀️ The 16:8 intermittent fasting method, known as time-restricted eating (TRE), proved effective for medium-term weight loss maintenance. Both early (9 a.m.-5 p.m.) and late (1 p.m.-9 p.m.) eating windows showed sustained benefits compared to usual eating patterns.

⚖️ Participants in the early-fasting group maintained a greater reduction in fat mass over the 12-month follow-up period. Researchers noted that over a third of participants continued intermittent fasting voluntarily, indicating its ease of integration into daily life.

#IntermittentFasting #WeightLoss #HealthTech

GLP-1 weight-loss medication is an important tool, but new results indicate that it cannot replace exercise. People with severe obesity who exercise regularly have healthier blood vessels and lower inflammation than those who rely on GLP-1 weight-loss medication alone.

Read Full Article

#WeightLoss #GLP1 #ExerciseScience

New research found people taking semaglutide for weight loss continued to consume significantly fewer calories after 60 weeks on the medication, helping explain how the medication supports both initial weight loss and long-term weight maintenance

Read Full Article

#WeightLoss #Semaglutide #CalorieRestriction

⭐ Penn Medicine study shows semaglutide maintains calorie reduction for over a year (60 weeks), aiding weight maintenance.

📉 Participants on semaglutide consistently ate 24-30% fewer calories than placebo group.

⚖️ Semaglutide group achieved average 15.1% weight loss over 60 weeks, compared to 3.4% for placebo.

💡 Study suggests appetite sensations may return, but medication continues to help reduce calorie intake for sustained weight loss.

#Semaglutide #WeightLoss #Health

Sex, Not Age, Predicts Weight Loss Outcomes With Tirzepatide: A Retrospective Analysis of 1,039 Patients Shows Female Sex Is an Independent Predictor of Greater Weight Loss, While Age Is Not

Read Full Article

#Tirzepatide #WeightLoss #SexDifferences

📊 A study of 1039 adults at Mayo Clinic (June 2022-May 2024) found that sex, not age, significantly predicts weight loss with tirzepatide. Women achieved greater weight loss (15.1%) compared to men (10.7%) after 15 months.

🧑‍⚕️ While younger patients (≤ 45 years) saw more weight loss than older patients (≥ 60 years), age was not an independent predictor in further analysis. Female sex, absence of type 2 diabetes, no prior obesity medication, and higher tirzepatide dosage were associated with greater weight loss.

💡 These findings suggest that sex should be a key consideration in personalized obesity treatment strategies using tirzepatide, as it plays a more significant role than age in predicting weight loss outcomes.

#Tirzepatide #WeightLoss #Obesity

Scientists discover a ‘skinny gene’ mutation that acts like Ozempic. Around one in 7,000 people carries a broken copy, which almost acts like a GLP-1 drug—the body burns fuel more efficiently, and the risk of disease lowers.

Read Full Article

#Genetics #WeightLoss #GLP1ergic

A promising new weight loss and diabetes treatment helps burn fat while keeping muscle

Read Full Article

#WeightLoss #DiabetesTreatment #FatBurning

🔬 UC Berkeley scientists have identified a molecular compound, TOFA, that helps cells burn extra energy, potentially aiding weight loss and diabetes treatment without changing food intake or exercise.

🔥 Unlike GLP-1 drugs that suppress appetite, TOFA works by increasing the body's metabolic rate. In mouse studies, it effectively lowered triglycerides, improved glucose control, and reduced fatty liver disease features, while preserving muscle mass.

🧬 TOFA acts as both an inhibitor of lipid production and an activator of genes that burn fat for energy, leading to a coordinated metabolic response observed in mice to burn up to 18% more energy.

🤝 When tested in combination with GLP-1 drugs like Ozempic/Wegovy and Mounjaro/Zepbound in mice, TOFA showed greater improvements in body weight, glucose control, and triglyceride levels than either treatment alone.

#WeightLoss #Diabetes #MetabolicHealth

* 🔬 An experimental compound, 5-tetradecyloxy-2-furoic acid (TOFA), has shown promise in mice by increasing the body's energy expenditure, leading to an average weight loss of 18% over four weeks without reducing food intake.

* 💪 TOFA appears to work by slowing fat production and helping cells burn fat for energy, preserving lean muscle mass. It also demonstrated benefits like lowered blood sugar, improved glucose response, and reduced blood and liver fat.

* 🤝 Combining TOFA with appetite-reducing drugs like semaglutide and tirzepatide resulted in greater weight loss and metabolic improvements in mice, suggesting a complementary approach to tackling obesity.

#WeightLoss #Obesity #Science

(⚠️ Formatting disabled due to Markdown error)

🥑 A study published in Cell Metabolism involving 42 adults with obesity, prediabetes, and excess liver fat found that a ketogenic diet was most effective for improving metabolic health, particularly liver health markers.

📊 Participants on a ketogenic diet achieved a 67% reduction in liver fat, compared to 45% for Mediterranean and low-fat diets. The keto group also saw a two to three times greater improvement in liver insulin sensitivity.

📈 Half of the participants on the ketogenic diet achieved prediabetes remission, significantly higher than the Mediterranean (29%) and low-fat (7%) diet groups.

🧠 Researchers were surprised that the ketogenic diet, despite being 73% fat, did not negatively impact blood cholesterol profiles and even tended to improve cardiovascular risk factors.

#KetoDiet #MetabolicHealth #WeightLoss

Our Fat Tissue May 'Remember' Obesity, Even After We've Lost Weight: Immune cells, located right inside fat tissue, can lead to permanent biological changes that directly interfere with fat loss, finds a new study that analyzed adipose tissue macrophages (ATMs) in mice.

Read Full Article

#WeightLoss #Metabolism #AdiposeTissue

GLP-1 weight-loss medication could slow aging and extend lifespan. Giving old mice semaglutide—commonly sold as Wegovy or Ozempic—extends their lifespan remarkably, a new study finds.

Read Full Article

#WeightLoss #AgingResearch #Semaglutide

🐭 A new study in healthy mice found the popular weight-loss drug semaglutide (Ozempic, Wegovy) alters brain activity and behavior related to reward and stress.

🧠 Daily doses of semaglutide in mice reduced interest in a natural reward (female mouse urine scent) and led to behaviors suggesting increased attempts to escape, less exploration, and improved stress resilience.

⚡ Brain wave recordings in anesthetized mice showed semaglutide shifted electrical patterns in the nucleus accumbens, a key brain region for reward processing, with slower brain waves becoming faster and less strong.

⚠️ The study's behavioral changes were observed only with daily injections, not weekly ones mirroring human prescriptions, and brain wave recordings were done under anesthesia, preventing a direct link to the observed behaviors.

#Semaglutide #WeightLoss #Neuroscience

Eli Lilly’s EloraTZP, a combination of eloralintide, a selective amylin receptor agonist, and tirzepatide, a dual GIP and GLP-1 receptor agonist, delivered greater weight loss and A1C reduction than tirzepatide alone at 48 weeks for adults with obesity and diabetes

Read Full Article

#WeightLoss #DiabetesCare #TirzepatideCEOlike2024

Survodutide Once Weekly in Adults with Obesity and Type 2 Diabetes | New England Journal of Medicine

Read Full Article

#WeightLoss #Obesity #Type2Diabetes

A 12-week clinical trial found that a daily supplement combining berberine, white mulberry extract, and chromium helped adults with obesity lose 2.35 kg of body fat and improve their insulin sensitivity by 28% compared to a placebo.

Read Full Article

#WeightLoss #InsulinSensitivity #ObesityCare

A new study has revealed that weight loss and diabetes medications like liraglutide alter how the body manages fluids by disrupting chemical signals between the brain and kidneys.

Read Full Article

#WeightLoss #DiabetesMedications #BrainKidneyConnection